sodium-bicarbonate and Developmental-Disabilities

sodium-bicarbonate has been researched along with Developmental-Disabilities* in 1 studies

Trials

1 trial(s) available for sodium-bicarbonate and Developmental-Disabilities

Article	Year
Pharmacokinetics of two formulations of omeprazole administered through a gastrostomy tube in patients with severe neurodevelopmental problems. British journal of clinical pharmacology, 2011, Volume: 72, Issue:6 Omeprazole is often administered through a gastrostomy tube as either (i) a Multiple Unit Pellet System (MUPS®) tablet disintegrated in water (MUPS® formulation), or (ii) a suspension in 8.4% sodium bicarbonate (suspension formulation). This bioavailability study evaluates this practice in tube-fed patients with severe neurodevelopmental problems.. Nonblinded, two-phase cross-over trial.. In seven of 10 patients, bioavailability was higher for the suspension formulation than for the MUPS® formulation. Median (90% confidence interval) area under the plasma concentration-time curve ratio (MUPS® over suspension) was 0.5 (0.06-2.37).. In this population, omeprazole MUPS® formulation has no apparent advantage over the more easily administered suspension formulation. Topics: Adolescent; Adult; Anti-Ulcer Agents; Biological Availability; Child; Cross-Over Studies; Developmental Disabilities; Enteral Nutrition; Female; Gastrostomy; Humans; Male; Omeprazole; Severity of Illness Index; Sodium Bicarbonate; Suspensions; Water; Young Adult	2011

Article

Year

Pharmacokinetics of two formulations of omeprazole administered through a gastrostomy tube in patients with severe neurodevelopmental problems.

British journal of clinical pharmacology, 2011, Volume: 72, Issue:6

Omeprazole is often administered through a gastrostomy tube as either (i) a Multiple Unit Pellet System (MUPS®) tablet disintegrated in water (MUPS® formulation), or (ii) a suspension in 8.4% sodium bicarbonate (suspension formulation). This bioavailability study evaluates this practice in tube-fed patients with severe neurodevelopmental problems.. Nonblinded, two-phase cross-over trial.. In seven of 10 patients, bioavailability was higher for the suspension formulation than for the MUPS® formulation. Median (90% confidence interval) area under the plasma concentration-time curve ratio (MUPS® over suspension) was 0.5 (0.06-2.37).. In this population, omeprazole MUPS® formulation has no apparent advantage over the more easily administered suspension formulation.

Topics: Adolescent; Adult; Anti-Ulcer Agents; Biological Availability; Child; Cross-Over Studies; Developmental Disabilities; Enteral Nutrition; Female; Gastrostomy; Humans; Male; Omeprazole; Severity of Illness Index; Sodium Bicarbonate; Suspensions; Water; Young Adult

2011